The Effect of Amiloride and Spironolactone in Patients With Hypertension

Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01388088

Acronym

hass

Enrollment

Registered

2011-07-06

Start date

2010-09-30

Completion date

2012-02-29

Last updated

2012-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Potassium, Blood-pressure

Brief summary

The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone. The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.

Detailed description

Purpose of the study is to examine the effect of amilorid and spironolacton on 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsewavevelocity, augmentation index and centralt bloodpressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory blood pressure

Interventions

DRUGSpironolactone

25 mg twice a day

DRUGAmiloride

5 mg twice a day

DRUGPlacebo

twice a day

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

45 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Hypertension * Age 45-70 * BMI: 18,5-30

Exclusion criteria

* Other diseases * Drug or alcohol abuse * Abnormal findings in the screening procedure

Design outcomes

Primary

Measure	Time frame	Description
Blood pressure	2 years	24 hours blood pressure measurements

Secondary

Measure	Time frame	Description
Pulse wave velocity	2 years	We will investigate the changes in cardiovascular variables using a Sphygmocor scanner.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026